13th Jul 2022 15:36
Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Opens its new custom-engineered laboratory in New York. The facility includes 10,000 rentable square feet of lab space, including two clean rooms for cell therapy manufacturing. Company says it is now able to manufacture cells in-house, accelerating and simplifying the commercialisation of its cell therapy product candidates. Intends to initially focus on the production of its HEMO-CAR T cell therapy for leukaemia.
Current stock price: 1.25 pence, up 2.2% in London on Wednesday afternoon
12-month change: down 40%
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Hemogenyx